Cogito-B (01167): The research data on the combined use of SHP2 inhibitor SITNEPROTAFIB has been published in an academic journal.

Zhitong Finance News APP reported that Jike Company-B (01167) announced that the company's independently developed SHP2 inhibitor sitneprotafib (JAB-3312) related research has been published in Clinical Cancer Research. The article disclosed preclinical in vitro and in vivo data of SHP2 inhibitors in combination therapy with PD-1 antibodies and targeted RTK/RAS/MAPK pathways, as well as representative patient cases responding to combination therapy.